RegCell Secures $66M for Immune Tolerance Trials

RegCell has secured $66M of additional support to move its immune-tolerance platform toward clinical development. The September 15, 2026 package combines a fully subscribed $44M Series A led by Playground Global with an approximately $22M second award from Japan's Agency for Medical Research and Development.

The financing brings private equity and non-dilutive public funding into the same clinical handoff. RegCell intends to use that support for an investigational new drug submission, clinical proof-of-concept work, a second generation of its epigenetic reprogramming platform, and an additional Phase 2 proof-of-concept study in another autoimmune indication.

The company was founded around Shimon Sakaguchi's discovery of regulatory T cells, work that helped earn him a share of the 2025 Nobel Prize in Physiology or Medicine. The science gives RegCell an unusual origin story; the capital now has to help convert that foundation into patient evidence.

What RegCell Announced

RegCell's official financing announcement separates the new support into 2 parts. Playground Global led the $44M Series A, joined by new investors Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, and Medical Incubator Japan. Existing investors Fast Track Initiative, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, and Kyoto iCAP also participated.

Jory Bell, a General Partner at Playground Global, joined RegCell's board as part of the financing. The approximately $22M / ¥3.4B AMED award is RegCell's second grant from the Japanese agency and is earmarked for the company's next-generation platform and an additional Phase 2 proof-of-concept study.

The intake headline described $66M as total funding, but the company calls it additional funding. RegCell previously announced a $45.8M package in 2025 consisting of an $8.5M seed round and up to $37.3M / ¥5.6B of AMED support first awarded in 2024. Across those 2 announcements, the company has publicly disclosed approximately $111.8M in equity financing and grant commitments: $52.5M of equity and approximately $59.3M from AMED.

That cumulative figure requires care. The earlier award was described as up to $37.3M and the second as approximately $22M, so $111.8M is an arithmetic summary of announced packages, not a claim that every grant dollar is already available as cash.

The Science Behind RegCell

Regulatory T cells, or Tregs, help prevent the immune system from attacking the body's own tissues. The Nobel Prize's account of the 2025 medicine award credits Sakaguchi with identifying a new class of regulatory T cells in 1995 and later helping establish how FOXP3 governs their development. He shared the prize with Mary E. Brunkow and Fred Ramsdell for discoveries concerning peripheral immune tolerance.

RegCell is attempting to translate that biology into cell therapies for autoimmune disease. Its platform is designed to take pathogenic T cells, which help drive a disease-specific immune attack, and epigenetically reprogram them into stable, antigen-specific regulatory T cells. The company says this approach does not require gene engineering and is intended to preserve healthy immune function rather than suppress immune activity broadly.

Those attributes are development claims, not established clinical outcomes. RegCell has not reported human efficacy or safety results for the platform in the new financing announcement. The current job is to move the technology through regulatory preparation and into trials capable of testing whether the selective mechanism survives manufacturing, dosing, and patient biology.

Why the Funding Mix Matters

Platform biotechnology spends capital long before it earns commercial revenue. Teams must establish manufacturing processes, analytical controls, regulatory packages, trial operations, and repeatable product quality while the biological thesis remains exposed to failure. Equity financing pays for the company that carries those risks, but every new round also changes ownership.

AMED's non-dilutive support changes that equation without removing the scientific risk. The agency's V-ECO program backs drug-development startups alongside investment from certified venture firms. RegCell's first AMED award supported its first-generation platform through clinical proof of concept in autoimmune liver diseases; the second expands the public commitment to approximately $59.3M and broadens the planned development work.

This is also a cross-border financing design. UTEC's RegCell profile traces the company to Japanese university science in January 2016. RegCell moved its headquarters to Emeryville, California, in 2025 while keeping scientific operations in Japan, giving the company access to U.S. clinical, regulatory, partnership, and capital networks without cutting the institutional roots that produced the platform.

The Clinical Handoff

President and CEO Michael V. McCullar is taking RegCell into a phase where development milestones matter more than scientific pedigree. The company says the new package will support an IND submission, advance its first-generation platform into clinical-stage development, accelerate a second-generation version, and fund an additional Phase 2 proof-of-concept study in a second autoimmune indication.

The announcement names myasthenia gravis, rheumatoid arthritis, and ulcerative colitis as examples of conditions where restoring immune tolerance could matter, but it does not identify each disease as a committed RegCell clinical program. It also leaves the lead indication, IND timing, trial sites, enrollment, and detailed allocation of proceeds undisclosed.

That is the correct boundary for interpreting the round. The capital establishes capacity and a development path; the trials will determine whether RegCell's reprogrammed cells can deliver the intended selectivity, stability, and clinical benefit. Nobel-recognized science can explain why investors and a national research agency are willing to fund the attempt, while patient data will decide what the platform becomes.

What This Signals for Autoimmune Cell Therapy

Autoimmune medicine has historically relied on broad suppression because the immune system's harmful and healthy activity can be difficult to separate. RegCell is part of a wider effort to make that control more precise by using the immune system's own regulatory machinery. If antigen-specific tolerance can be produced reliably, the commercial and clinical promise would extend beyond symptom management toward more durable control of disease.

The obstacles are equally specific. Autologous cell therapies must be manufactured consistently, delivered through a workable clinical process, and evaluated indication by indication. A platform designed to avoid gene engineering may simplify parts of that path, but RegCell still needs evidence on product quality, safety, persistence, dosing, and efficacy.

The $66M package gives RegCell more room to answer those questions and adds institutions with different tolerances for time and risk. Playground Global is underwriting the company-building side. AMED is extending a public commitment to the research journey. RegCell now carries a scientific lineage from Japanese immunology into a U.S.-based clinical organization, and the quality of that handoff will be measured in the data it can produce.